PLX (Protalix BioTherapeutics) Shiller PE Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
54 GF Score
Price $2.33
GF Value $2.21
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protalix BioTherapeutics  (AMEX:PLX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Protalix BioTherapeutics Shiller PE Ratio Related Terms


Protalix BioTherapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Shiller PE Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PLX vs GLSI, DTIL, NERV: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Shiller PE Ratio falls into.


PLX
54GF Score
Protalix BioTherapeutics Inc PLX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Protalix BioTherapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Protalix BioTherapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.05/333.9520*333.9520
=0.050

Current CPI (Jun. 2026) = 333.9520.

Protalix BioTherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.700 241.428 -0.968
201612 -0.200 241.432 -0.277
201703 -4.800 243.801 -6.575
201706 -0.600 244.955 -0.818
201709 -0.900 246.819 -1.218
201712 -0.870 246.524 -1.179
201803 -0.500 249.554 -0.669
201806 -0.600 251.989 -0.795
201809 -0.400 252.439 -0.529
201812 -0.400 251.233 -0.532
201903 -0.500 254.202 -0.657
201906 -0.520 256.143 -0.678
201909 -0.240 256.759 -0.312
201912 0.020 256.974 0.026
202003 0.100 258.115 0.129
202006 -0.130 257.797 -0.168
202009 -0.140 260.280 -0.180
202012 0.030 260.474 0.038
202103 -0.140 264.877 -0.177
202106 -0.250 271.696 -0.307
202109 -0.090 274.310 -0.110
202112 -0.140 278.802 -0.168
202203 -0.050 287.504 -0.058
202206 -0.110 296.311 -0.124
202209 -0.070 296.808 -0.079
202212 -0.070 296.797 -0.079
202303 -0.050 301.836 -0.055
202306 0.210 305.109 0.230
202309 -0.040 307.789 -0.043
202312 -0.100 306.746 -0.109
202403 -0.060 312.332 -0.064
202406 -0.030 314.175 -0.032
202409 0.030 315.301 0.032
202412 0.090 315.605 0.095
202503 -0.050 319.799 -0.052
202506 0.000 322.561 0.000
202509 0.030 324.800 0.031
202512 -0.070 324.054 -0.072
202603 0.220 330.213 0.222
202606 0.050 333.952 0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.33 is trading 5.4% above its estimated GF Value™ of $2.21. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for PLX:

  • Shiller PE Ratio:
  • GF Value™: $2.21 vs. price of $2.33 (5.4% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score

Get the complete analysis for PLX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price
$2.21
GF Value